Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
BIOXYTRAN announced that the first patients have been treated with ProLectin-M in its dose optimization trial. ProLectin-M is intended to become a first line treatment for standard risk COVID-19 patients, but based on the broad-spectrum in vitro discovery could easily expand to upper respiratory tract infections.
February 21, 2024